Does Insulin Glargine Interact with Latanoprost Ophthalmic Solution 0005?
CDI records a moderate classification for Insulin Glargine and Latanoprost Ophthalmic Solution 0005. The stored summary is: Combined use of two or more prostaglandins or prostaglandin analogs not recommended. Administration more than once daily may decrease IOP lowering effect or cause paradoxical IOP elevations. The mechanism involves unknown mechanism for iop effect reduction or paradoxical elevation. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Insulin Glargine Class
- Insulin Analog
- Latanoprost Ophthalmic Solution 0005 Class
- Prostaglandin Analog
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Unknown mechanism for IOP effect reduction or paradoxical elevation
What To Tell Your Doctor or Pharmacist
If you are taking Insulin Glargine and your doctor is considering prescribing Latanoprost Ophthalmic Solution 0005 (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider